KVA12123,Pembrolizumab
kineta bio,Merck
['biomarker', 'kva12123']
 cso, thierry guillaudeux, unveiled new vista biomarker data and kva12123 phase 1/2 clinical trial update at the 2023 annual meeting. click on the link below to access the poster presentation. 
Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives